Business Context and Reporting Period
This Form 8-K Current Report, dated January 21, 2005, covers events occurring on January 20, 2005. The registrant is Corporate Road Show.Com Inc., a New York corporation. The filing announces a material definitive agreement to merge with Rexahn, Corp, a Maryland biopharmaceutical company focused on signal inhibitor drug therapies for cancer. Upon completion, the combined entity will be reincorporated in Delaware and renamed "Rexahn Pharmaceuticals, Inc."
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Corporate Road Show.Com Inc. or Rexahn, Corp. This report focuses exclusively on the terms of the proposed merger and corporate restructuring.
Material Changes and Transaction Terms
- Merger Structure: Corporate Road Show.Com Inc. will merge with Rexahn, Corp via a wholly-owned subsidiary (CRS Merger Sub, Inc.). Rexahn will be the surviving corporation and a wholly-owned subsidiary of the new parent.
- Reverse Stock Split: The Company will effect a 1-for-100 reverse stock split immediately prior to the merger.
- Reincorporation: The Company will reincorporate in Delaware under the name Rexahn Pharmaceuticals, Inc.
- Exchange Ratio: Each share of Rexahn common stock will convert into five shares of Rexahn Pharmaceuticals common stock. Existing options will be converted to options for the new entity.
- Post-Merger Ownership: Current Rexahn stockholders will own approximately 91.8% of the new entity, while current Corporate Road Show.Com Inc. stockholders will own approximately 8.2%.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the expected completion of the transactions, which are subject to known and unknown risks. The consummation of the merger is contingent upon several conditions, including:
- Approval by Rexahn stockholders.
- Approval by Corporate Road Show.Com Inc. stockholders for the reverse stock split and reincorporation.
- Execution of a Settlement Agreement between Frank Ferraro and the Company.
- Other customary closing conditions.
Management explicitly states there can be no assurance that the transactions will be consummated. Investors are directed to read the upcoming proxy statement for further details on risks and management interests.
Key Facts for Investor Verification
- Verify the approval status of the merger by Rexahn and Corporate Road Show.Com Inc. stockholders.
- Confirm the execution of the Settlement Agreement between Frank Ferraro and the Company.
- Review the upcoming proxy statement for detailed financial data on Rexahn, Corp, which is not included in this 8-K.
- Monitor the status of the 1-for-100 reverse stock split and the Delaware reincorporation process.
- Check for any dissenting shareholder actions that could impact the transaction timeline.